Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto, Largo Professor Abel Salazar no. 2, 4099-003 Porto, Portugal.
Departmento de Biologia & CESAM, Universidade de Aveiro, Campus Universitario de Santiago, 3810-193 Aveiro, Portugal.
Mar Drugs. 2011;9(10):1860-1886. doi: 10.3390/md9101860. Epub 2011 Oct 10.
Marine invertebrates are rich sources of bioactive compounds and their biotechnological potential attracts scientific and economic interest worldwide. Although sponges are the foremost providers of marine bioactive compounds, cnidarians are also being studied with promising results. This diverse group of marine invertebrates includes over 11,000 species, 7500 of them belonging to the class Anthozoa. We present an overview of some of the most promising marine bioactive compounds from a therapeutic point of view isolated from cnidarians in the first decade of the 21st century. Anthozoan orders Alcyonacea and Gorgonacea exhibit by far the highest number of species yielding promising compounds. Antitumor activity has been the major area of interest in the screening of cnidarian compounds, the most promising ones being terpenoids (monoterpenoids, diterpenoids, sesquiterpenoids). We also discuss the future of bioprospecting for new marine bioactive compounds produced by cnidarians.
海洋无脊椎动物是生物活性化合物的丰富来源,其生物技术潜力引起了全世界的科学和经济兴趣。虽然海绵是海洋生物活性化合物的主要提供者,但腔肠动物也在被研究,并取得了有希望的结果。这组多样化的海洋无脊椎动物包括超过 11000 种,其中 7500 种属于珊瑚纲。我们从治疗的角度概述了一些在 21 世纪第一个十年中从腔肠动物中分离出来的最有前途的海洋生物活性化合物。柳珊瑚目和海鸡冠目迄今为止表现出最高数量的产生有前途化合物的物种。抗肿瘤活性一直是腔肠动物化合物筛选的主要关注领域,最有前途的化合物是萜类化合物(单萜、二萜、倍半萜)。我们还讨论了未来从腔肠动物产生的新海洋生物活性化合物的生物勘探前景。